Company / Cash & Equivalents
AMICUS THERAPEUTICS, INC. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$214.0M
FY2025
5-year range
$148.8M / $247.0M
FY2021-FY2025
Trend
+0.1%
vs FY2024
Sector context
#82 of 207
Health Care
What the data says
At $214M, AMICUS THERAPEUTICS, INC.'s cash & equivalents ranks #82 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $49M in FY2017 to $247M in FY2023.
Based on SEC 10-K filings.
$214M in FY2025 with a 5-year CAGR of +5.6%.
Declined from $247M to $214M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +12.9%
- 5-Year CAGR
- +5.6%
- 10-Year CAGR
- -
Sector benchmark
#82 of 207 in Health CareTop 40% of 207This company $214.0M Sector average $669.5M
▼
-68.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.6%, indicating consistent growth.
- In FY2025, cash & equivalents increased 0.1% year-over-year.
- Ranks #82 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.19 (distress zone, below 1.8 threshold)
- Negative profit margin: -10.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $214.0M | +0.1% |
| FY2024 | $213.8M | -13.5% |
| FY2023 | $247.0M | +66.0% |
| FY2022 | $148.8M | -39.3% |
| FY2021 | $245.2M | +50.2% |
| FY2020 | $163.2M | +14.3% |
| FY2019 | $142.8M | +79.1% |
| FY2018 | $79.7M | +62.6% |
| FY2017 | $49.1M | -73.8% |
| FY2016 | $187.0M | +169.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026